News from Our Members

October 18, 2017 - (Quad) - Quad Technologies announced today the U.S. Patent and Trademark Office has awarded the company a new U.S. Patent, No. 9,790,467, titled “Methods and Compositions for activation or expansion of T lymphocytes”. According to Quad Technologies CEO Sean Kevlahan, the patent relates to a scalable T-lymphocyte culture reagent that helps streamline CAR-T by eliminating the need for magnetic beads and the downstream “debeading” unit operation.
June 22, 2016 - (Synpromics) - Synpromics Ltd, the leading synthetic promoter company, is pleased to announce an extension to the original collaboration with uniQure announced in January 2015, which focused on the development of synthetic promoters with up-regulated liver cell specific activity suitable for gene expression using an AAV vector.
October 28, 2015 – (CBMG) – Cellular Biomedicine Group Inc. (NASDAQ: CBMG) announced results from an ongoing Phase IIa clinical trial evaluating the safety, feasibility and anti-tumor activity of its acquired Chimeric Antigen Receptor-Modified T-Cells immunotherapy targeting CD20 for the treatment of patients with advanced B-cell non-Hodgkin lymphoma. 
October 28, 2015 – (BioCision) – BioCision, LLC, today announced a collaboration with the University of California, San Francisco Transplantation Research Laboratory of Dr. Qizhi Tang, who is researching a novel transplantation immunotherapy that could potentially minimize rates of organ rejection and the toxicity of global immunosuppression; a similar strategy is being investigated for the treatment of autoimmune diseases including Type 1 diabetes.
October 28, 2015 – (Cesca) – Cesca Therapeutics, Inc.(NASDAQ:KOOL) announced that its subsidiary, TotipotentRX, has signed a multi-year distribution agreement with Miltenyi Biotec GmbH for clinical product sales throughout India.  
October 28, 2015 – (Cellectis) – Cellectis (Alternext: ALCLS – Nasdaq: CLLS) today announced that a series of three production runs of UCART19, its lead TALEN gene edited product candidate, was performed, confirming the implementation of Cellectis’ manufacturing process in GMP conditions. 
October 27, 2015 – (Kite) – Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences, Inc., a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer.